Lincoln Pharmaceuticals Share Price

Lincoln Pharma.

CMP as on 16-May-22 15:29

₹ 303.55
7.05 2.38%

Open

₹ 305.00

Turnover (lac)

₹ 34

Prev. Close

₹ 296.50

Day's Vol (shares)

₹ 11,231

Day's Range (₹)

₹ 296.00
₹ 305.00

CMP as on16-May-22 15:28

₹ 304.75
10 3.39%

Open

₹ 302.10

Turnover (lac)

₹ 105

Prev. Close

₹ 294.75

Day's Vol (shares)

₹ 675

Day's Range

₹ 295.70
₹ 304.75

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 02-Feb-2022 - -
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2022 inter alia to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and nine months ended on December 31 2021 along with any other business if any. OUTCOME OF BOARD MEETING (As Per BSE Announcement Dated on 10/02/2022)
Board Meeting - 03-Nov-2021 - -
Quarterly Results Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015, we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Thursday, November 11, 2021, have considered and approved the un-audited financial results (Standalone and Consolidated) of the Company along with the limited review reports for the quarter and half year ended on September 30, 2021. Further, we enclose herewith financial highlights of the Company for the aforesaid quarter. (As Per BSE Announcement Dated 11.11.2021)
Board Meeting - 30-Sep-2021 - -
inter-alia to transact the following businesses: 1) To issue/ allot equity shares to the eligible shareholders of Lincoln Parenteral Ltd. pursuant to Scheme of Amalgamation of Lincoln Parenteral Limited (Transferor Company) and Lincoln Pharmaceuticals Limited (Transferee Company) and their respective shareholders and creditors, under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 as approved by the Honble National Company Law Tribunal, Ahmedabad Bench vide its order dated September 14, 2021. 2) Any other item may be taken up for consideration with the permission of the Chairman and with the consent of a majority of the Directors present in the Meeting, if any. With reference to the above captioned subject, we would like to inform you that the board of directors of the Company at its meeting held today i.e. on Tuesday, October 05, 2021, which commenced at 5:30 p.m. and concluded at 6:20 p.m. inter-alia considered and approved the following: - Allotment of 29,728 equity shares of face value of Rs. 10/- each of the Company pursuant to the scheme of amalgamation of Lincoln Parenteral Limited (Transferor Company) and Lincoln Pharmaceuticals Limited (Transferee Company) and their respective shareholders and creditors (Scheme), as approved by the Honble National Company Law Tribunal, Ahmedabad Bench vide its order dated September 14, 2021. Further, it is noted that the 98,58,438 (Ninety Eight Lacs Fifty Eight Thousand Four Hundred Thirty Eight) equity shares of Transferor Company held by the Company (Transferee Company) shall be cancelled without any act, deeds or instrument. (As Per BSE Announcement dated on 05.10.2021)
Board Meeting - 30-Jul-2021 - -
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2021 ,inter alia, to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter ended on June 30, 2021 along with any other business, if any. Pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, trading window has been closed for trading in securities of the Company from July 01, 2021 and shall reopen after the expiry of 48 hours from the time the result becomes generally available. We would like to inform that the Board of Directors of the Company at its meeting held today i.e. Tuesday, August 10, 2021, have considered and approved the un-audited financial results of the Company (Standalone and Consolidated) along with the limited review report for the quarter ended on June 30, 2021. Further, we enclose herewith financial highlights of the Company for the aforesaid quarter. (As Per BSE Announcement dated on 10.08.2021)
Board Meeting - 17-May-2021 - -
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2021 ,inter alia, to consider and approve the audited standalone and consolidated financial results of the Company for the quarter and year ended on March 31, 2021 and recommendation of dividend on equity shares of the Company, if any, along with any other business, if any. Further, in continuation to our disclosure on closure of trading window dated March 31, 2021, pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, trading window has been closed for trading in securities of the Company from April 01, 2021 and shall reopen after the expiry of 48 hours from the time the result becomes generally available. Lincoln Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 25, 2021, inter alia, has recommended a dividend of Rs. 1.50/- (i.e. 15% per share) per equity share of face value of Rs. 10.00/- for the year ended March 31, 2021, for approval of the members at the ensuring Annual General Meeting (AGM) of the Company. we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Tuesday, May 25, 2021, have considered / approved / recommended, inter alia, the followings: (1) audited financial results (standalone and consolidated) for the quarter and year ended on March 31, 2021 along with the reports of auditors thereon. Recommended a dividend qf ~ 1.50/- (i.e. 15% per share) per equity share of face value of ~ 10.00/- for the year ended March 31, 2021, for approval of the members at the ensuring Annual General Meeting (AGM) of the Company. We also enclose herewith financial highlights of the Company for the aforesaid quarter. (As Per BSE Announcement Dated on 5/25/2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity